- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00266279
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine have not been defined. The aim of this Phase II study is to determine the response rate of combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with Head and Neck cancer for which there is no curative treatment.
The study also aims to determine the qualitative and quantitative toxicity and reversibility of toxicity of the above combination and to evaluate any changes in performance status, quality of life, overall survival and progression-free survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville, James Graham Brown Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell cancer of Head and Neck
- Patients must have metastatic or locally recurrent disease
- Patients must have disease not curable by surgery as estimated by one of the protocol investigators, and should not be eligible for reradiation protocol or have failed reradiation protocol.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan
- Age >18 years of age
- Life expectancy of greater than 12 weeks
- ECOG performance status 0, 1 or 2 (Karnofsky >50%; see Appendix B)
Patients must have adequate bone marrow function as defined below:
- absolute neutrophil count > 1,500
- platelets > 100,000
- hemoglobin > 8 g/dl
Patients must have adequate renal function as defined by a creatinine clearance >30 mL/min (measured or estimated by the Cockroft and Gault equation)
- Cockroft and Gault equation:
- Creatinine clearance for males =(140-age[yrs])(body wt[kg])/72(serum creatinine[mg/dL])
- Creatinine clearance for females = 0.85 x male value
Patients must have adequate liver function as defined below:
- total bilirubin 1.5x upper limit of normal
- albumin > 2.5 g/dl
- AST(SGOT) and ALT(SGPT) and Alkaline Phosphatase must be < 5 times upper limit of normal
- Patients could have received 1 or 2 previous chemotherapy regimens prior to entering the study. Patients must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Alopecia may not be resolved and peripheral neuropathy (grade 1) may be present.
- Patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil or oxaliplatin
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to first treatment in this study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients receiving any other investigational agent(s)
- Patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis (because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events)
- Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ
- Clinically significant cardiac disease (e.g. congestive heart failure, New York Heart Association Class II or greater, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.
- If patient is unable to swallow, xeloda may be crushed per hospital policy/procedure. See attached Appendix G.
- Patients who have had an organ allograft.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy
- Known Hepatitis B , Hepatitis C, HIV
Inclusion of Minorities:
Members of all ethnic groups are eligible for this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with Study Drugs
Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
|
Agent, DOSE AND SCHEDULE (28-days cycle): Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Overall Response Rate (ORR)=PR+CR. |
Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative and Quantitative Toxicity
Time Frame: At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Number of patients that developed common side effect of diarrhea.
|
At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Damian Laber, M.D., University of Louisville, James Graham Brown Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 153.05
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head or Neck Cancer
-
University Hospital, GhentFund for Scientific Research, Flanders, BelgiumCompleted
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Centre Hospitalier Universitaire, AmiensRegional Council PicardieCompletedHead and Neck Cancer | Microsurgery | Head and Neck Reconstructive Surgery | Head and/or Neck Shotgun Trauma | Bone Free FlapFrance
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Hospices Civils de LyonInternational Agency for Research on CancerRecruitingLung or Head and Neck CancerFrance
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
Clinical Trials on Oxaliplatin, Capecitabine
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Chonnam National University... and other collaboratorsCompletedColorectal CancerKorea, Republic of
-
Hebei Medical UniversityCompletedGastroesophageal Junction AdenocarcinomaChina
-
Samsung Medical CenterCompleted
-
Hebei Medical UniversityUnknownGastric Cancer | Liver MetastasisChina
-
AIO-Studien-gGmbHiOMEDICO AGTerminated
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.Unknown
-
Hebei Medical UniversityUnknownGastroesophageal Junction AdenocarcinomaChina
-
Hebei Medical UniversityUnknownLiver Metastasis | HER-2 Positive Gastric CancerChina
-
University of Southern CaliforniaBristol-Myers Squibb; Sanofi; Roche Global DevelopmentUnknownGastric Cancer | Esophageal CancerUnited States
-
Royal Marsden NHS Foundation TrustCompletedColorectal CancerUnited Kingdom